Results

1–2 of 2 results for phase 3 randomized clinical trial

ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design andRationale Informed by Outcomes From ARCHER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2025
Efficacy and Safety of CT-P42 Compared to Reference Aflibercept (AFL) in Diabetic Macular Edema (DME): 24-Week Results From the Phase 3 CT-P42 3.1 Study
David M. Brown, MD
Annual Meeting Talks
2023